Healthy, Ketogen-based Therapeutic Diet, Metabolic Abnormalities
Conditions
Keywords
ketogenic diets, intermittent fasting, metabolic health
Brief summary
A cross-study analysis combined data from two sequential pre-post intervention studies conducted at the University of Tennessee at Martin, yielding a three-arm design comprising intermittent fasting alone (n = 16), clean ketogenic diet alone (n = 22), and combined clean ketogenic diet with intermittent fasting (n = 41). The clean ketogenic diet restricted carbohydrate intake to 20 grams per day from whole unprocessed sources and eliminated refined sugars, high-fructose corn syrup, and ultra-processed foods.
Detailed description
The intermittent fasting protocol employed a 16:8 time-restricted eating window. Paired-samples t-tests examined within-group pre-to-post changes. One-way analyses of variance with Tukey post-hoc comparisons examined between-group differences in magnitude of change. Effect sizes are reported as Hedges' g for within-group comparisons and eta-squared for between-group comparisons. An independent samples t-test compared glycosylated hemoglobin changes between the intermittent fasting and combined groups. Spearman and Kendall correlations examined associations between fat mass and cardiometabolic change.
Interventions
intervention was either clean keto, intermittent fasting 16:8 schedule or a combination of both
Sponsors
Study design
Masking description
it was a blind study for the researcher who was analyzing the data
Intervention model description
three arm design comparing 3 interventions (low carb, intermittent fasting, combined) between group design
Eligibility
Inclusion criteria
\-
Exclusion criteria
* pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of HDL Cholesterol | Baseline and 30 days | Fasting Blood draw to assess high-density lipoprotein cholesterol levels |
| Concentration of Serum Triglycerides | baseline and 30-days | Fasting blood draw to assess serum triglyceride levels |
| Concentration of Hemoglobin A1c (HbA1c) | Baseline and 30 days | Blood draw to assess HbA1c as a marker of glycemic control |
Countries
United States